<DrugInformationSummary id="CDR0000754956"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about ibrutinib
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib">Ibrutinib</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000638648">Ibrutinib</TerminologyLink><GlossaryLink ref="CDR0000754851">ibrutinib</GlossaryLink><USBrandNames><USBrandName>Imbruvica</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>i-BROO-tih-nib</TermPronunciation><MediaLink ref="CDR0000757958" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000757957" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Ibrutinib</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Ibrutinib
         is approved 
         to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">Chronic lymphocytic leukemia</GlossaryTermRef></Strong> and <Strong><GlossaryTermRef href="CDR0000407751" dictionary="Cancer.gov" audience="Patient">small lymphocytic lymphoma</GlossaryTermRef></Strong>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">Chronic lymphocytic leukemia</GlossaryTermRef></Strong> and <Strong><GlossaryTermRef href="CDR0000407751" dictionary="Cancer.gov" audience="Patient">small lymphocytic lymphoma</GlossaryTermRef></Strong>  that  has a chromosome change called <GlossaryTermRef href="CDR0000810645" dictionary="Cancer.gov" audience="Patient">17p deletion</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044854" dictionary="Cancer.gov" audience="Patient">Waldenstr√∂m macroglobulinemia</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef>).</ListItem></ItemizedList>
  <Para id="_4">Ibrutinib
         is also being studied in the treatment of other types of
         cancer and other conditions.</Para>
 </Section><Section id="_About"><Title>More About Ibrutinib</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/638648">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.26">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a614007.html">Ibrutinib</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.27"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.28">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy">Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C81934">Find Clinical Trials for Ibrutinib</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2013-12-16</DateFirstPublished><DateLastModified>2023-04-10</DateLastModified></DrugInformationSummary>
